Fast-Growth Biotechs

Making critical site decisions without enterprise infrastructure

Fast-growth biotech teams often reach a point where investigator selection becomes unavoidable. As programs move into Phase II and beyond, identifying the right sites and investigators is mission-critical, but the infrastructure to support that work may not exist yet.

SunshineMD helps emerging biotech teams access high-quality investigator intelligence without committing to long-term licenses or building internal data capabilities from scratch.

When trials outpace internal resources

Early clinical programs are frequently built around a small group of investigators. As trials expand, that model breaks down.

Biotech teams may be working toward funding milestones with limited time and limited margin for error. They need to identify credible investigators quickly, often for the first time, and they cannot afford to open sites that fail to enroll.

Why traditional options don’t fit

Many feasibility tools and data platforms are designed for large organizations with ongoing trial portfolios.

For fast-growth biotechs, those solutions can be misaligned:

  • Long-term contracts for one-time or infrequent needs
  • Complex platforms that require setup and training
  • High costs that are difficult to justify for a single study

As a result, teams are often left piecing together investigator lists manually or relying heavily on CRO recommendations without independent validation.

How SunshineMD supports fast-growth biotech teams

SunshineMD provides right-sized access to investigator performance intelligence when teams need it most.

Biotech teams use SunshineMD to:

  • Identify investigators with relevant experience for a specific study
  • Validate CRO-recommended site lists
  • Focus outreach on investigators more likely to contribute
  • Move from planning to execution quickly

Engagements can be scoped to fit the needs of a single trial or milestone rather than a long-term licensing commitment.

What changes for fast-growth biotechs

With clearer investigator insight upfront, teams can:

  • Move faster without sacrificing confidence
  • Avoid opening unnecessary or underperforming sites
  • Make site selection decisions grounded in documented history
  • Preserve capital and focus resources where they matter most

See SunshineMD in practice

To see how SunshineMD supports fast-growth biotech teams preparing for clinical expansion, request a demo.

Explore how investigator performance data can help you move into your next phase with greater clarity and speed.